Beyond COVID-19 Spending Growth, Biosimilars Slowed Growth In Other Categories
IQVIA Finds Non-COVID Drug Spending Up Just 5%
Executive Summary
The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.
You may also be interested in...
BioNTech Buoyant On CAR-T/CARVac Combo Data
CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
Moderna Sees Key Role For Respiratory Vaccines As COVID-19 Goes Endemic
The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.
2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy
Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.